Royalty Pharma Plc (RPRX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Royalty Pharma Plc  (NASDAQ: RPRX)


Royalty Pharma Plc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Royalty Pharma Plc's ROA in the second quarter of 2026?
Royalty Pharma Plc achieved a return on average assets (ROA) of 17.07 % in its second quarter of 2026, this is above RPRX's average return on assets of -39.64%.
Royalty Pharma Plcs assets during the 12 months ending in the second quarter of 2026 are valued at $7 billion

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 131 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 931, from total ROA ranking in the first quarter of 2026 at 1068.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 6.21 % 51.11 % 31.68 % 21.44 % 442.14 %
Y / Y Net Income Change 153.25 % 8.03 % 6.45 % -44.91 % -83.45 %
Net Income (TTM) in million 1,350 1,301 1,266 1,244 1,606
Return On Assets (TTM) 17.07 % 17.1 % 17.35 % 17.61 % 23.23 %
RPRX's Total Ranking # 931 # 1068 # 908 # 702 # 625
Total Assets (TTM) in million 20,671 3,680 3,831 3,457 19,463
Seq. Total Assets Change 461.74 % -3.95 % 10.84 % -82.24 % 699.21 %
Seq. Net Income Change -82.6 % 31.56 % -19.88 % 1280.57 % -92.58 %

RPRX's 5 Years Annual ROA >> Back to RPRX Management Effectiveness >> Compare RPRX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 51
Sector # 132
Overall # 907

Return On Assets Statistics
High Average Low
15.43 %
-39.64 %
-230.49 %
(Sep 30 2020)   (Sep 30 2017)





Financial Statements
Royalty Pharma Plc's Assets $ 20,671 million RPRX's Balance sheet
Royalty Pharma Plc's Income $ 81 million Quarterly RPRX's Income Statement
RPRX's Income by Division See RPRX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 31.68 % 38.93 % -34.74 % -9.08 % 5.16 %
Total Assets in million 3,831 2,910 2,094 3,209 3,530
Y / Y Net Income Change -0.5 % -21.72 % 638.96 % -81.46 % -27.07 %
Net Income in million 1,324 1,331 1,700 230 1,241
Annual Return On Assets 34.56 % 45.74 % 81.18 % 7.17 % 35.16 %

RPRX's 5 Years Annual ROA >> Back to RPRX Management Effectiveness >> Compare RPRX ROA to its Competitors



Comment on RPRX's ROA in the fiscal year ending 2025
In the fiscal year 2025 Royalty Pharma Plc's ROA decreased compared to previous year to 34.56 %, due to deterioration of net income -0.5 % to $1,324.19 million, from $1,330.81 million a year ago, as RPRX's assets were $3,831.30 million.


More Return On Assets Ratios
RPRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RPRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RPRX's Competitors
Subscribers only: Roa for Royalty Pharma Plc's Suppliers
Subscribers only: Return On Assets for RPRX's Customers

You may also want to know
RPRX's Roi RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons
RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %

Date modified: 2026-09-08T15:11:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.